ELEV•benzinga•
Elevation Oncology To Discontinue Development Of EO-3021; Continuing To Advance Potentially Differentiated HER3 ADC, EO-1022, Which Utilizes An MMAE Payload And Glycan Site-Specific Conjugation
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 20, 2025 by benzinga